What is Cancer?

• Authorization for Release of Health Information
• Medication List Form
• Referring and Primary Care Physician Information Sheet
• Patient Registration Form – Part 1
• Patient Registration Form – Part 2
• Clinical Trials and Insurance Coverage – Understanding Out of Pocket Cost for Clinical Trial Participation
• Notification & Acknowledgement of Patient Financial Responsibilities
• Advance Care Planning and Directives Questionnaire
• Daily Activity Questionnaire 

At Mary Crowley Cancer Research, we believe that your health information is personal. We keep records of the care and
services that you receive at our facilities. We are committed to keeping your health information private, and we are
also required by law to respect your confidentiality.

Please click below for a copy of the Notice of Privacy Practices:

• Notice of Privacy Practices
• Acknowledgement of Receipt of Notice of Privacy Practices
• Notice/Acknowledgement of Privacy Practices (TOPA)

For more information about your health information privacy rights, click HERE.

Your Cancer Journey at Mary Crowley Cancer Research

MOLECULAR TESTING: ROADMAP TO CANCER

Most people agree that using a Google™ map or similar navigation device ensures that a traveler will reach their destination accurately and more quickly than without such guidance.  Next Generation Genomic Sequencing (NGS) represents the current, state-of-the-art molecular test and works like a roadmap for physicians and their cancer patients.

Molecular testing through NGS is routinely ordered for each patient at Mary Crowley that has a tissue sample of their tumor from an earlier surgery. The results identify the gene alterations/biomarkers that contribute to the patient’s cancer growth and act as a roadblock to traditional cancer treatments. Identification of gene mutations is valuable for the physician, but only with accurate interpretation and correlated therapies that address the molecular signature of the patient. With this information, a patient can be appropriately aligned to a matching therapy designed to impact that mutation or cancer signal (see below for an example of how this works in a Foundation One™ partial report).

All patient sequencing results are maintained in a dynamic Patient Molecular Registry at Mary Crowley and regularly assessed for a potential clinical trial match.  Additionally, any patient may request Mary Crowley to conduct NGS of a portion of their surgical tumor in the event they may need a research option, if needed, after their initial cancer surgery and standard treatment.